Combination Therapy for Radiation-Induced Bone Marrow Aplasia in Nonhuman Primates Using Synthokine SC-55494 and Recombinant Human Granulocyte Colony-Stimulating Factor.

摘要

Combination cytokine therapy continues to be evaluated in an effort to stimulate multilineage hematopoietic reconstitution after bone marrow myelosuppression. This study evalu- ated the efficacy of combination therapy with the synthetic interleukin-3 receptor agonist, Synthokine-SC55494, and recombinant methionyl human granulocyte colony-stimulating factor (rhG-CSF) on platelet and neutrophil recovery in nonhuman primates exposed to total body 700 cGy 60Co gamma radiation. After irradiation on day (d) 0, cohorts of animals subcutaneously received single-agent protocols of either human serum albumin (HSA; every day OD), (15 microng/kg/d. n = 10). Synthokine (twice daily BID), (100 microng/kg/d, n = 5), rhG-CSF (QD, 10 microng/kg/d, n = 5). or a combination of Synthokine and rhG-CSF (BID, 100 and 10 microng/kg/d, respectively, n = 5) for 23 days beginning on dl. Complete blood counts were monitored for 60 days postirradiation and the durations of neutropenia absolute neutrophil count.